Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05455931 · ClinicalTrials.gov registry record

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)

A clinical trial of Mycosis Fungoides and Sézary Syndrome, sponsored by Kyowa Kirin Pharmaceutical Development.

Active
Registry status
73
Enrollment target
19
Study locations

NCT05455931 is a study of Mycosis Fungoides and Sézary Syndrome that is active but no longer recruiting, run by Kyowa Kirin Pharmaceutical Development. The registered enrollment target is 73 participants. The trial reports 19 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05455931, a study of Mycosis Fungoides and Sézary Syndrome, is active but no longer recruiting, sponsored by Kyowa Kirin Pharmaceutical Development.

ACTIVE NOT RECRUITING
Registry status
73 participants
Enrollment target
19
Study locations

Study Summary

This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.

Interventions

  • DRUG Poteligeo

Study Locations (19)

Other

  • Azienda Ospedaliero Universitaria Ospedali Riuniti Do Ancona - Ancona
  • IRCCS A.O.U. Policlinico S. Orsola - Malpighi - Bologna
  • Azienda Ospedaliero- Universitaria Careggi - Florence
  • Ematologia Policlinico di Milano - Milan
  • IFO-San Gallicano IRCCS - Rome
  • Universita Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli - Rome
  • Leids Universitair Medisch Centrum (LUMC) - Leiden
  • Hospital Del Mar - Barcelona
  • Hospital Universitari de Bellvitge - Barcelona
  • Sheikh Shakhbout Medical City - Abu Dhabi
  • Clatterbridge Hospital - Wirral University Teaching Hospital Nhs Foundation Trust - Bebington
  • University Hospital Birmingham - Birmingham
  • The Christie NHS Foundation Trust - Manchester
  • Nottingham University Hospitals NHS Trust - Nottingham City Hospital - Nottingham

Maryland

  • The Johns Hopkins University School of Medicine - Baltimore

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Colombia University Medical Center - New York

Virginia

  • Inova Dwight and Martha Schar Cancer Institute - Fairfax

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2022-11-09
Est. Completion 2025-08-07

What the Registry Record Tells You About NCT05455931

The ClinicalTrials.gov registry entry for NCT05455931 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Pharmaceutical Development, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mycosis Fungoides and Sézary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Poteligeo is the first listed.

NCT05455931 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, Maryland, Missouri.

Frequently Asked Questions

What is clinical trial NCT05455931 about?

NCT05455931 is a clinical study titled "Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)". This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.

What is the current status of trial NCT05455931?

This trial is currently active not recruiting. The enrollment target is 73 participants. The study started on 2022-11-09. Estimated completion is 2025-08-07.

What conditions does trial NCT05455931 study?

This clinical trial studies the following conditions: Mycosis Fungoides and Sézary Syndrome.

What interventions are being tested in trial NCT05455931?

The interventions under investigation include: Poteligeo (DRUG).

Who is sponsoring clinical trial NCT05455931?

This trial is sponsored by Kyowa Kirin Pharmaceutical Development, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05455931 being conducted?

This trial has 19 study locations across Maryland, Missouri, New York, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.